News from debiopharm international sa A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages

Latest

08 Nov, 2019, 08:00 GMT Debiopharm Progresses in Their Stand Against Drug-resistant N. Gonorrhoeae With Extended CARB-X Funding of Their Debio 1453 Antibiotic Program

Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company, announced today it has been awarded the 2nd phase funding from the Combating...


09 Oct, 2019, 07:00 BST A Pancreatic and Colorectal Cancer Trial Initiated to Address the Needs of Patients With Immune Checkpoint Inhibitor (ICI)-resistant Disease by Combining Debiopharm's Debio 1143 IAP Antagonist With Keytruda®

Debiopharm (www.debiopharm.com) announced today the first patient enrolment in a Phase I study initiated by Dr. Phillippe Cassier, combining the...


30 Sep, 2019, 09:00 BST Debiopharm's Novel IAP Antagonist Debio 1143 Achieves Outstanding Phase II Results for High-risk Head and Neck Cancer Patients

Debiopharm, a Swiss-based global biopharmaceutical company, presented today, at the ESMO Congress (European Society for Medical Oncology), compelling ...


03 Sep, 2019, 08:00 BST Debiopharm Successfully Completes Randomized Phase II Study for IAP Antagonist Debio 1143 in High Risk Head and Neck Cancer Patients

Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company, announced positive topline results across clinical endpoints following the...


09 Jul, 2019, 08:00 BST Debiopharm and BIOASTER Join Forces to Expand Research to Combat Infectious Diseases

Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company, and BIOASTER (www.bioaster.org), the French Technology Research Institute in...


03 Jun, 2019, 08:00 BST Caris Life Sciences Partners with Debiopharm International SA to Develop Companion Diagnostic for Detection of Rare FGFR Fusions Using Novel Molecular Intelligence (MI) Transcriptome™

Caris Life Sciences®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, today announced that it has...


21 May, 2019, 08:00 BST Debiopharm Expands Its Immuno-oncology Development Program for Debio 1143, With the First IAP Inhibitor/Nivolumab Combination Trial

Debiopharm (www.debiopharm.com) announced today the first patient enrolled in SMARTPLUS-106, an exploratory study investigating the safety and...


16 May, 2019, 13:00 BST GenePOC Obtains FDA Clearance for Its GenePOC™ Carba Test in the US

GenePOC announces FDA clearance of its molecular diagnostic test for the detection and differentiation of the five most frequent gene sequences...


14 May, 2019, 13:00 BST Debiopharm Awarded $2.1 Million from CARB-X in the Fight Against a Highly Resistant Nosocomial-pneumonia Causing Superbug

Debiopharm (www.debiopharm.com) announced today that it has been awarded funding from the Combating Antibiotic-Resistant Bacteria Biopharmaceutical...


30 Apr, 2019, 17:22 BST GenePOC, a Subsidiary of Debiopharm Group, Reaches an Agreement With Meridian Bioscience for the Acquisition of Their Molecular Diagnostics Business

Debiopharm (www.debiopharm.com), announced today having reached an agreement with Meridian Bioscience, Inc. for Meridian to acquire GenePOC's...


11 Apr, 2019, 08:00 BST GenePOC Obtains CE Marked for Its GenePOC™ Carba Test

GenePOC Inc., member of the Debiopharm Group, announces its third test to be CE marked, the GenePOC Carba assay, to be used with the revogene™ device....


21 Mar, 2019, 13:00 GMT GenePOC Obtains FDA Clearance for Its GenePOC™ Strep A Test in the US

GenePOC Inc., member of the Debiopharm Group, announces its third test to be cleared by the FDA, the GenePOC Strep A assay, to be used with the...


26 Feb, 2019, 08:00 GMT Debiopharm International SA Initiates a Clinical Trial Phase II Study Evaluating afabicin in Bone and Joint Infections

Debiopharm International SA (Debiopharm – www.debiopharm.com/debiopharm-international/), part of Debiopharm Group™, a Swiss-based global...


14 Feb, 2019, 08:00 GMT Debiopharm International SA Initiates FUZE, a Clinical Trial Phase II Study Evaluating Debio 1347 in Advanced Solid Tumors Harboring an FGFR Fusion

Debiopharm International SA (Debiopharm – www.debiopharm.com/debiopharm-international/), part of Debiopharm Group™, a Swiss-based global...


23 Oct, 2018, 13:00 BST GenePOC® Launches its GenePOC® CDiff Test in Canada

GenePOC announces the Health Canada approval and launch of its molecular diagnostic test for the detection of Clostridium difficile in Canada GenePOC ...


11 Oct, 2018, 11:00 BST Debiopharm International SA and the Paul Scherrer Institute Announce a Licensing Agreement for the Development of a Novel Targeted Radiotherapeutic Product in Oncology

Debiopharm International SA (Debiopharm), a Swiss-based biopharmaceutical company and the Paul Scherrer Institute (PSI), the largest research...


08 May, 2018, 08:00 BST FDA Grants Fast Track Designation to Debiopharm International's Debio 1347 for the Treatment of Patients With Unresectable or Metastatic Tumors With a Specific FGFR Gene Alteration

Debiopharm International SA (Debiopharm - www.debiopharm.com), part of Debiopharm Group™, a Swiss-based global biopharmaceutical company, announced...


05 Apr, 2018, 08:06 BST Kaiku Health Raises €4.4 Million Series A Financing to Accelerate Its Digital Therapeutics Pipeline Led by Debiopharm and Tesi

Finnish digital health company Kaiku Health Oy, which provides intelligent patient monitoring software for healthcare providers across Europe, has...


19 Feb, 2018, 13:00 GMT GenePOC Launches Its revogene™ Instrument and GBS LB Test in Canada

GenePOC Inc., member of the Debiopharm Group™, is proud to announce the launch in its home market for the revogene instrument and the GenePOC™ GBS LB ...


15 Feb, 2018, 08:00 GMT Debiopharm Continues the Fight Against Antibiotic Resistance With Investment in ABAC Therapeutics Inc.

ABAC develops new targeted antibiotics for patients with severe infections Debiopharm Group ™ announces an investment in antibiotic development with...


28 Nov, 2017, 13:00 GMT GenePOC Launches its GenePOC™ CDiff Test in the United States

GenePOC announces the launch and FDA clearance of its Clostridium difficile molecular test in US. GenePOC Inc. (GenePOC), a member of the Debiopharm...


22 Nov, 2017, 08:00 GMT Debiopharm International SA Launches Clinical Trials Website: patients.debiopharm.com

The website provides patients with helpful information on the company's clinical trials Debiopharm International SA (Debiopharm -...


14 Nov, 2017, 08:00 GMT EMA Grants Orphan Drug Designation to Debiopharm International SA's FGFR Inhibitor Debio 1347 in the Treatment of Biliary Tract Cancer

Debiopharm International SA (Debiopharm - http://www.debiopharm.com), part of Debiopharm Group™, a Swiss-based global biopharmaceutical company,...


06 Nov, 2017, 08:00 GMT Debiopharm International SA Announces Dosing of First Patient in a Combination Trial of Debio 1143 and Avelumab in Patients with Solid Tumors Including Non-Small Cell Lung Cancer (NSCLC)

The clinical trial is in collaboration with the Merck-Pfizer Alliance Debiopharm International SA (Debiopharm - http://www.debiopharm.com), part of...


12 Oct, 2017, 09:00 BST GenePOC Launches its new GenePOC™ GBS DS Test

GenePOC announces the launch of its Group B Streptococcus Direct Swab (DS) molecular test in Europe GenePOC, Inc. (GenePOC), a member of the...